These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9263528)

  • 1. A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.
    Miyauchi A; Egawa S; Futami H; Kuma K; Obara T; Yamaguchi K
    Jpn J Cancer Res; 1997 Jun; 88(6):527-31. PubMed ID: 9263528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
    Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
    Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
    Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
    J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
    Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
    Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas.
    Scurini C; Quadro L; Fattoruso O; Verga U; Libroia A; Lupoli G; Cascone E; Marzano L; Paracchi S; Busnardo B; Girelli ME; Bellastella A; Colantuoni V
    Mol Cell Endocrinol; 1998 Feb; 137(1):51-7. PubMed ID: 9607728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas.
    Zedenius J; Larsson C; Bergholm U; Bovée J; Svensson A; Hallengren B; Grimelius L; Bäckdahl M; Weber G; Wallin G
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3088-90. PubMed ID: 7559902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
    Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
    Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
    Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
    Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.